Zervimesine
What it is & what research shows
Study example availableZervimesine is an investigational oral small molecule studied in dementia. Its proposed sigma-2 receptor mechanism aims to limit toxic protein interactions with neurons. SHIMMER tested safety and exploratory outcomes in Lewy body dementia. A separate START trial studies early Alzheimer’s disease; these populations and outcomes should not be combined. [1.1][1.2][1.3][1.4]
One selected study: A double-blind phase 2 study tested zervimesine safety and exploratory efficacy in Lewy body dementia. 130 randomized adults aged 50–85 with probable mild-to-moderate Lewy body dementia; 109 completed the study. Zervimesine 100 mg, 300 mg or placebo over 26 weeks. Exploratory outcomes showed favorable trends. Adverse-event discontinuations were 4.5% with 100 mg, 16.3% with 300 mg and 4.8% with placebo. Exploratory efficacy requires larger confirmatory trials. Findings do not establish dementia reversal, Alzheimer’s efficacy or healthy-person cognitive enhancement. [2.1]
Sources & reading scope
- [1.1] SHIMMER: zervimesine in Lewy body dementiaPublished human study · Randomized phase 2 trial; safety and exploratory clinical outcomes.
- [1.2] SHIMMER full paperPublished human study · Open-access report of the same trial, not a separate cohort.
- [1.3] SHIMMER trial recordTrial registration · Study design and any posted results; registration does not establish treatment benefit.
- [1.4] START: early Alzheimer’s disease trialTrial registration · Study design and any posted results; registration does not establish treatment benefit.
- [2.1] Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB).Human · Abstract summarized · not a full-paper review
Evidence summarized on PED Evidence
1 completed summaries
1 human-study reports
1 randomized-trial candidates
1 safety-topic reports
Studies & trial records
Original papers, trial registrations and sponsor disclosures are labeled separately. Multiple links may describe the same study.
More about Zervimesine: identity, safety & reference details
Also known as CT1812 · CT-1812
Start with the research
An outcome-specific synthesis has not been prepared for this compound. This is a coverage gap, not evidence that it has no effect.
Open studies and trial records- Uses & research
SHIMMER tested safety and exploratory outcomes in Lewy body dementia. A separate START trial studies early Alzheimer’s disease; these populations and outcomes should not be combined. [1][2][3][4]
- Known half-life
No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.- Evidence & important limits
The early trial supports further testing rather than established disease modification. Higher-dose treatment had more adverse-event discontinuations than placebo. Results in people with dementia do not establish a cognitive-enhancement effect in healthy adults. [1][2][3][4]
Safety & evidence boundaries
The early trial supports further testing rather than established disease modification. Higher-dose treatment had more adverse-event discontinuations than placebo. Results in people with dementia do not establish a cognitive-enhancement effect in healthy adults.
Explore safety questions by system
These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.
Identity, names & formulations
Canonical compound: Zervimesine · zervimesine
Searchable names: CT1812, CT-1812
Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
- Randomized human trials
- Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
- Controlled human studies
- Use a comparison group; allocation and confounding still matter.
- Prospective human research
- Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
- Observational human research
- Describes associations. Confounding can explain differences.
- Case reports and series
- Useful for unusual events and safety signals, not reliable rates or effect sizes.
- Animal research
- Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
- Cell and tissue research
- Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
- Mechanistic and computational evidence
- Helps explain or predict a pathway; predictions need experimental and clinical testing.
- Anecdotal reports
- Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.
Sources for this profile
- 1. SHIMMER: zervimesine in Lewy body dementia Published human study · Randomized phase 2 trial; safety and exploratory clinical outcomes.
- 2. SHIMMER full paper Published human study · Open-access report of the same trial, not a separate cohort.
- 3. SHIMMER trial record Trial registration · Study design and any posted results; registration does not establish treatment benefit.
- 4. START: early Alzheimer’s disease trial Trial registration · Study design and any posted results; registration does not establish treatment benefit.
Reference facts checked 2026-09-24. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.
Study model describes the source. Confidence depends on methods, replication, population and outcome.
Loading compound research…
Zervimesine study summaries
Human-first reading order. Intervention candidates are distinguished from background mentions in the library.